TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Patient-reported benefit from animal-assisted activity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean fasting plasma homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of mechanical restraint (MR)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of healing at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean % reduction in slough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drop out rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Markers of bone turnover (Pyd:Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: cystocele stage improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bulge symptom improvement expectation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: absence of chronic pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of serum E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of serum LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of serum FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total scores of climacteric syndrome
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CGI scores reflecting severity of illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume doubling time (VDT) for lung cancer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 6 min walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver enzymes (SGOT/SGPT)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life and well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Insulin-like growth factor-1 standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood glucose 2-3h after meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of ropivacaine and bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life of ropivacaine and bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first bowel sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increased serum gastrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of NPPV failure
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of residual ST-segment deviation <0.2 mV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 50% reduction on the Hamilton Depression Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wake time after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: overall severity score from the Sleep Clinical Global Impression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum alkaline phosphatase (ALP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: staff-rated leadership for EBP implementation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Core temperature (T re)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher completion of adjuvant treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in depressive symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Prescription adequacy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 30 days and 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Recurrent myocardial infarction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion of the extension
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post-ERC pancreatitis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Pancreatitis-related hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular end-diastolic volume index (RVEDVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological stress among carers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: placement of the patient in an institution
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thrombolysis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined 30-day death and severe adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: CSI, WMSI, CDL/LV, and WML/LV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic acute phase protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for T2D screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value for T2D screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for T2D screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total morphine consumption at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelli Robson contrast sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LogMAR reading acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary embolism (PE) diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to fulfillment of discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of postoperative seroma
Endpoint domain: Adverse events/effects
Primary endpoint: EMQ-p scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental QALY loss
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: BMDTB SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMADLS SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain relief after one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental component of the Short Form 36
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall survival (OS) benefit
Endpoint domain: Mortality/survival
Primary endpoint: Total effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Vascular resistance (PI and RI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of delusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Elastic recovery of skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Aortic valve stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deep vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occupational performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Amblyopic eye visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with amblyopic eye visual acuity 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per percent LDL-C reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EQ‐5D utility index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PQoL‐12 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: VAS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensory disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective knowledge and skills rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective measure of assessment skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-to-F physical assault frequency
Endpoint domain: Adverse events/effects
Primary endpoint: M-to-F sexual coercion
Endpoint domain: Adverse events/effects
Primary endpoint: female physical injury
Endpoint domain: Adverse events/effects
Primary endpoint: LRTI incidence
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of incontinence-free patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health related quality of life assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: post-void residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean oral fluid/blood ratios of oxazepam and oxazepam glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean saving per patient per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: death or myocardial infarction or unstable angina requiring hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Median number of pain crises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Functional Class (FC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Craving-associated compulsivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceptual aspects of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive aspects of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UL efficacy of febuxostat 80 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical cure rate at the end of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's anxiety level before axillary brachial plexus block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal oxygen shortfall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean gross motor developmental quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mouth opening stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First intubation attempt success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Airway visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: space closure velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during eating
Endpoint domain: Adverse events/effects
Primary endpoint: microTBS of Clearfil SE Bond to dentin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime pain symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug-assisted erectile function (EF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end diastolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of transformation within the mandibular geometric configuration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relief of overall irritable bowel syndrome symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improvement of abdominal discomfort/pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total score on PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 30% decrease in SUVpeak assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% decrease in CT diameter assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first occurrence of any major bleeding event
Endpoint domain: Adverse events/effects
Primary endpoint: composite of myocardial infarction, stroke or death from vascular causes
Endpoint domain: Mortality/survival
Primary endpoint: Physical activity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in appraisals of past harm
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival rate of grafted skin
Endpoint domain: Mortality/survival
Primary endpoint: Mobility of the CTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: occupational sitting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of AROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EGF in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4 and CD8 levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morning PEFR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total nasal symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mini‐rhinoconjunctivitis quality of life questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: nasal endoscopy index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced externalizing behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Movement Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected distance acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected near acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean contrast acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dissatisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Size of surgically excised CNV specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Histologic diagnosis of CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in COD performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 30-m sprint speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural knowledge gain
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean maximal decrease in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metastases-free survival
Endpoint domain: Mortality/survival
Primary endpoint: horizontal clinical attachment level gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 50 percent improvement at nine months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of MI-consistent statements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change talk about physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reported physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bacteriologic eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA-IR (Homostatic Model Assessment–insulin resistance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in angina and heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diarrhea as a dose limiting factor
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic exposure to SN-38
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: factor VIIc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: factor VIIIc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total 6-month excess costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 2-year ischemic outcomes
Endpoint domain: Mortality/survival
Primary endpoint: clinically relevant bleeding outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Knee swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood nevirapine concentrations below 100 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predose infant nevirapine concentrations below 100 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Flexion Angle (KFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full recovery from IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dyadic sexual desire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean anterior capsule opening area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eradication efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ulcer healing efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in ketamine-evoked BOLD phMRI signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DASH questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Anemia risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron deficiency (ID) risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron deficiency anemia (IDA) risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in S mutans concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general psychopathological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caregiver health/well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Western Aphasia Battery Aphasia Quotient (WAB‐AQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: gliclazide AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gliclazide clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gliclazide half-life (t(1/2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage times intragastric pH < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Error learning in aphasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Knee Replacement (TKR)
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of episodic hypercalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hypercalciuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes